See the DrugPatentWatch profile for osimertinib
What is Osimertinib Mesylate?
Osimertinib mesylate is a medication used to treat certain types of non-small cell lung cancer (NSCLC). It specifically targets tumors with mutations in the epidermal growth factor receptor (EGFR) gene, particularly the T790M resistance mutation [1].
Why is Osimertinib Mesylate Expensive?
The cost of osimertinib mesylate, marketed as Tagrisso by AstraZeneca, is influenced by several factors common to novel cancer therapies. These include the significant investment in research and development, extensive clinical trials required for regulatory approval, and the complexity of manufacturing the drug. The drug’s targeted nature and its effectiveness in a specific patient population also contribute to its pricing [2].
When Does Osimertinib Mesylate Patent Protection End?
The patent landscape for osimertinib mesylate is complex and can vary by region. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceuticals like osimertinib mesylate [3]. Generally, brand-name drugs like Tagrisso have patent protection that prevents generic versions from entering the market for a set number of years. However, patent challenges and settlements can alter these timelines [4].
Can Generic Versions of Osimertinib Mesylate Be Cheaper?
The introduction of generic versions of a drug typically leads to lower prices due to increased competition. For osimertinib mesylate, the availability of a generic alternative would depend on the expiration of its relevant patents and any associated market exclusivity. Once generic competition begins, prices are expected to decrease significantly [3, 4].
What Are the Alternatives to Osimertinib Mesylate?
For patients with EGFR-mutated NSCLC, treatment options can vary depending on the specific mutation profile and prior treatments. Other EGFR tyrosine kinase inhibitors (TKIs) exist, such as erlotinib, gefitinib, and afatinib, which may be used in earlier lines of therapy or for different mutation types. Immunotherapy and traditional chemotherapy are also treatment modalities for NSCLC, often used in combination or for patients without specific EGFR mutations [5].
How Does Osimertinib Mesylate Work?
Osimertinib mesylate functions as a third-generation EGFR tyrosine kinase inhibitor. It works by selectively inhibiting both EGFR-sensitizing mutations and the T790M resistance mutation, which can develop after treatment with earlier EGFR TKIs. By blocking these mutated proteins, it prevents cancer cells from growing and dividing [1].